drugset / Trial / NCT00881153

To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.

NCT00881153

Phase 1 Completed 20 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.

Timeline

Start
2004-05
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CEFPROZIL ANHYDROUS, (E)- Small molecule 10 ml Oral

Indications

No indication recorded.